1-20 of 27
Authors: Jean-Michel Molina
Save search
Sort by
Journal Article

Transmission of S230R integrase drug resistance mutation affecting second-generation integrase inhibitors in a French primary HIV-1 infected man

PDF
Maud Salmona and others
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 7, July 2023, Pages 1802–1803, https://doi.org/10.1093/jac/dkad135
Published: 06 May 2023
Journal Article

Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR study

PDF
Geoffroy Liegeon and others
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 12, December 2022, Pages 3427–3435, https://doi.org/10.1093/jac/dkac336
Published: 07 October 2022
Journal Article

Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial

PDF
Lauriane Goldwirt and others
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 10, October 2021, Pages 2675–2680, https://doi.org/10.1093/jac/dkab253
Published: 19 July 2021
Journal Article

Identification of 16S rRNA mutations in Mycoplasma genitalium potentially associated with tetracycline resistance in vivo but not selected in vitro in M. genitalium and Chlamydia trachomatis

PDF
Chloé Le Roy and others
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 5, May 2021, Pages 1150–1154, https://doi.org/10.1093/jac/dkab016
Published: 04 February 2021
Journal Article

Safety and efficacy of fumagillin for the treatment of intestinal microsporidiosis. A French prospective cohort study

PDF
Alexis Maillard and others
Journal of Antimicrobial Chemotherapy, Volume 76, Issue 2, February 2021, Pages 487–494, https://doi.org/10.1093/jac/dkaa438
Published: 30 October 2020
Journal Article

Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study

PDF
François Raffi and others
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 6, June 2020, Pages 1618–1622, https://doi.org/10.1093/jac/dkaa056
Published: 25 March 2020
Journal Article

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial

PDF
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 3, March 2020, Pages 628–639, https://doi.org/10.1093/jac/dkz479
Published: 21 November 2019
Journal Article

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study—authors’ response

PDF
Christine Katlama and others
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 12, December 2020, Pages 3699–3700, https://doi.org/10.1093/jac/dkaa341
Published: 20 September 2019
Journal Article
EDITOR'S CHOICE

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study

PDF
Christine Katlama and others
Journal of Antimicrobial Chemotherapy, Volume 74, Issue 9, September 2019, Pages 2742–2751, https://doi.org/10.1093/jac/dkz224
Published: 03 July 2019
Journal Article

Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia

PDF
Christophe Rodriguez and others
Journal of Antimicrobial Chemotherapy, Volume 73, Issue 11, November 2018, Pages 3122–3128, https://doi.org/10.1093/jac/dky315
Published: 20 August 2018
Journal Article

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study

PDF
Minh P Lê and others
Journal of Antimicrobial Chemotherapy, Volume 73, Issue 8, August 2018, Pages 2120–2128, https://doi.org/10.1093/jac/dky193
Published: 13 June 2018
Journal Article

Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

PDF
Jean-Michel Molina and others
Journal of Antimicrobial Chemotherapy, Volume 73, Issue 8, August 2018, Pages 2129–2136, https://doi.org/10.1093/jac/dky181
Published: 01 June 2018
Journal Article

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial

PDF
Julien Fonsart and others
Journal of Antimicrobial Chemotherapy, Volume 72, Issue 2, February 2017, Pages 478–485, https://doi.org/10.1093/jac/dkw412
Published: 28 September 2016
Journal Article

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

PDF
S. Lambert-Niclot and others
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 4, April 2016, Pages 1056–1062, https://doi.org/10.1093/jac/dkv427
Published: 24 December 2015
Journal Article
EDITOR'S CHOICE

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial

PDF
Olivier Lortholary and others
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 3, March 2016, Pages 783–793, https://doi.org/10.1093/jac/dkv384
Published: 17 December 2015
Journal Article

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response Get access

PDF
Charlotte Charpentier and others
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 7, July 2015, Pages 2090–2096, https://doi.org/10.1093/jac/dkv048
Published: 08 March 2015
Journal Article

Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations Get access

PDF
Thi Thu Nga Nguyen and others
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 3, March 2015, Pages 731–738, https://doi.org/10.1093/jac/dku424
Published: 21 October 2014
Journal Article

High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients Get access

PDF
Victoire de Lastours and others
Journal of Antimicrobial Chemotherapy, Volume 68, Issue 8, August 2013, Pages 1850–1856, https://doi.org/10.1093/jac/dkt125
Published: 18 April 2013
Journal Article

Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study Get access

PDF
Matthieu Lafaurie and others
Journal of Antimicrobial Chemotherapy, Volume 67, Issue 4, April 2012, Pages 1010–1015, https://doi.org/10.1093/jac/dkr555
Published: 11 January 2012
Journal Article

Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study Get access

PDF
Li Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 67, Issue 2, February 2012, Pages 465–468, https://doi.org/10.1093/jac/dkr490
Published: 25 November 2011